CTLA4 and neoplasm: As expected, depleting CD8+ T cells using anti-CD8α mAb prevented tumor rejection on anti-CTLA-4 antibody treatment (Figure 1c,d), indicating that ICI-mediated rejection of YTN16 was dependent on CD8+ T cell responses.